Ala Coaster
Arovella Therapeutics intends to be a world leader as a biotechnology company helping people live longer and healthier lives.

Arovella Therapeutics is a biotechnology company developing its iNKT cell therapy platform for blood cancers, solid tumours, autoimmune disease.
arovella.comCrawled Nov 11, 2026
Arovella Therapeutics intends to be a world leader as a biotechnology company helping people live longer and healthier lives.
Arovella Therapeutics’ ALA-101 targets blood cancers like lymphoma and leukemia using CAR19-iNKT cell therapy.
Arovella’s CLDN18.2-iNKT cell therapy targets gastric, pancreatic, and other cancers.
Arovella Therapeutics develops iNKT cell therapies targeting blood cancers and solid tumors.
The page describes iNKT cell therapy and its potential in treating solid tumors with engineered immune cells.
Arovella Therapeutics publishes research on iNKT cell cancer therapies and recent scientific advancements.
Arovella Therapeutics Ltd Annual General Meeting was held at 11:00am AEDT in person and virtually via an online platform. Full details of the meeting can be found in the Notice of Annual General Meeting dated 5 October 2026. View results of meeting View CEO presentation View recording of AG
The page lists analyst coverage for Arovella Therapeutics (ASX: ALA).
Arovella Therapeutics appointed Dr. Nicole Van Der Weerden as Chief Executive Officer.
Arovella Therapeutics ASX: ALA
Highlights: Arovella’s CAR-iNKT cells demonstrated potent anti-tumour activity in a model of advanced gastric cancer Five out of seven (71%) animals treated with the cells survived and showed no sign of tumours after 60-days versus 0% for the control groups. Cytokine armoured cells in
The page shares updates on Arovella Therapeutics’ iNKT cell therapies and research.
ESG Reports from Arovella Therapeutics ASX: ALA
Arovella Therapeutics provides contact details for inquiries about immunotherapy solutions and research collaborations.
Arovella names **Dr. Nicole van der Weerden** as its new Chief Executive Officer, effective immediately. The appointment follows the company’s leadership transition. Dr. van der Weerden brings executive experience to guide Arovella’s strategic direction.
Arovella enrolls the first patient in its phase 1 clinical trial of ALA-101, an off-the-shelf cell therapy designed to treat blood cancers. The milestone marks progress in developing a potentially universal treatment option for patients with hematologic malignancies. ALA-101 leverages engineered immune cells to target cancerous blood cells without requiring patient-specific modifications.
Arovella Therapeutics secures a **$4.03 million** R&D tax incentive refund for FY2026, boosting its cash reserves. The company advances its **lead asset development** and prepares for **first-in-human dosing**. The funds support ongoing clinical progress in its pipeline.
Charles River Laboratories supports Arovella Therapeutics with next-generation sequencing (NGS) services to advance cancer treatment research. The partnership strengthens Charles River’s focus on client collaboration and alternative development methods in oncology. Both companies aim to expedite therapeutic innovations through advanced genomic analysis.
Arovella Therapeutics secures full funding for Phase 1 clinical trials of its lead drug candidate, **ALA-101**, after raising **$20 million** through a share placement at **$0.17 per share** in the December quarter. The capital commitment enables the company to advance its clinical development without additional financing needs. ALA-101 remains the focal program in Arovella’s pipeline.
Arovella secures a **$20 million placement** at **$0.17 per share**, a **2.9% discount** to its last trade. The funding fully supports the completion of **Phase 1** of its operations. The capital raises follow firm commitments from investors.